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Ambidextrous Supply Chain Strategy and Business Performance: a 
pharmaceutical wholesaler perspective.  
 
E. Lambourdière 1, E. Corbin 2 and C. Savage 3, 1&2 Department of Transportation and Supply Chain 
Management, Institute of Technology, University of French West Indies. 3 Division of Transport and 
Logistics, University of Huddersfield  
Abstract 
Wholesale distributors in the United Kingdom and the United States are aware of the magnitude of the 
changes that have taken place in medicine distribution systems. They have responded with innovative 
logistics strategies to deal with this highly competitive environment. Their new services rely on an 
ambidextrous supply chain strategy (i.e. exploitative and explorative logistics innovation). This 
research explored those innovative processes and the results concluded that wholesale distributors 
are developing practices to achieve a high level of operational efficiency, which at the same time 
develop new logistics solutions to provide a competitive advantage, thereby securely maintaining their 
position in the drug supply chain.  
Keywords: Pharmaceutical supply chains, pharmaceutical wholesalers, logistics innovation, 
ambidextrous supply chain strategy. 
Introduction 
Wholesale distributors located in the United Kingdom and the United States are having to face an 
increase in the level of uncertainty in pharmaceutical supply chains. Previously physical flows of 
medicines in the state systems were relatively uninhibited, but now both countries’ governments are 
more reluctant to reimburse drug costs. In addition, other players, such as generic producers or 
logistics service providers, have appeared in the drug supply chain, and these have further 
complicated the business environment of U.S. and UK firms. Drug manufacturers in these countries 
are already attuned to the innovation required to deal with the ever changing logistics environment that 
continues to evolve. This is clearly demonstrated by the continual emergence of new management 
practices in the pharmaceutical supply chain in both countries. Wholesale distributors, responsible for 
the logistics, cannot ignore the changes taking place and, further, they are actively trying to develop 
innovative logistics strategies of their own. Thus, in order to survive and compete within their supply 
chains, they continually reassess the already ample logistics services they offer to their clients. The 
novel logistics services processes developed by wholesale distributors are based on a clever and 
complex mixture of exploitative innovation and explorative innovation. Therefore, this paper will 
demonstrate how this mix enables apparently moribund wholesale distributors have used strategies of 
incremental and radical innovation to secure their position in the pharmaceutical supply chain as well 
as improving their market share. Further, it should be noted that this has been achieved during an era 
that was supposed to destroy disintermediation. 
Research areas 
For a number of years, the environment surrounding the pharmaceutical supply chain has become 
increasingly complex. Technological innovation, mostly in the field of chemical engineering, is often 
regarded as the only solution that can be suggested to the drug producer. Logistics innovation as a 
solution is beginning to be explored by a growing number of actors operating in the UK and USA drug 
supply chains. This research concerns mainly the building of logistics innovation in supply chains, from 
the perspective of British and American wholesale distributors. 
Methodology 
In this work, innovation has been identified as the introduction of a new service offer or the use of new 
technologies to improve the competitive position of the company within the pharmaceutical supply 
 2 
chain. This development, if carried out successfully, will enable the companies in question to become 
securely entrenched in the drug supply chain. Thus, the construction, deployment and reconstruction 
of innovative services are the strategic elements that enable the British and American wholesale 
distributors to improve their position in the pharmaceutical supply chain. The main analysis examines 
pharmaceutical supply chains using the concept of the ambidextrous supply chain strategy (Kristal et 
al., 2010). Kristal investigated the influence of an ambidextrous supply chain strategy on 
manufacturers’ combinative competitive capabilities, which is defined as “the ability to excel 
simultaneously on competitive capabilities of quality, delivery, flexibility, and cost and, in turn, on 
business performance” (Kristal et al., 2010). From this perspective, the evolution of logistics services 
appears to be based on exploitative and explorative innovation processes (He, Wong, 2004; Chanal, 
Mothe, 2004). 
Exploitative innovation is intended to improve and / or extend an offer made by a company to its 
customer. This improvement may be related to products, services, processes, etc.. Companies taking 
this route expect immediate results and tend to then embark on short-term strategic changes. 
Exploitative innovation, in turn, allows the company to maintain profitability and stabilize its position in 
a market in which it is already working. Taking advantage of core competencies of the business and 
organizational routines are very important components of exploitative innovation. These lead the 
company in a direction for which long term commitment is essential. The company that involves itself 
in such an approach will seek to introduce radical changes to its service production. Innovation 
exploration should allow the company to face the future with confidence. These changes will 
materialize in response to the introduction of new services and technologies to enhance the 
company’s customer service offering. Such changes, which can be described as revolutionary, are 
generally made to allow the company using them to enter new markets and / or reach new customers. 
Explorative innovation can materially affect the technology trajectory and organizational routines of 
those applying them. If well done, it should enable the improvement of the company’s sustainability. 
It appears that the British and American wholesale distributors are innovative in developing both 
supply chain exploitation and exploration strategies. By creating new services, they pursue strategies 
for supply chain exploration, as well as developing standardized services or expanding the existing 
ones, they develop new strategies for supply chain exploitation. It is this agile link between exploitative 
and explorative innovation in the supply chain that leads to an ambidextrous supply chain strategy 
(Kristal, Huang, Roth, 2010). 
A matrix has been developed to enable the processing of the data collected during the investigations – 
see figure1. When this matrix was completed, it enabled the assessment of how ambidextrous a 
supply chain strategy is. The approach to logistics is considered from a holistically and strategic point 
of view where management strategy is based on two practices: one within the supply chain operations 
and the other across boundaries.  
Figure 1: Characteristics and impacts of innovation strategies  
developed by pharmaceutical wholesalers 
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Source: the authors 
 
Other theories such as “competitive growth theory” (Roth, 1996), the development of combinatorial 
capacity, the theories of dynamic capabilities of knowledge-based view and the Law of Requisite 
Variety are also considered to carry out the data analysis. The interrogation of these theories has 
allowed us to add two more entries in our matrix. These two entries are the combinative comparative 
capabilities and business performance. Data were gathered from archival and secondary data as 
recommended by Calantone and Vickery (2010). 
Results and Discussion:  
Results  
Traditionally simply responsible for administering pharmaceutical distribution, wholesaler distributors 
now seek regular innovation in logistics to develop strategies that are operational-logistics and 
business-sales driven in order to increase the volume of sales in their supply chain. Whereas the 
“original” wholesaler-distributors were not market oriented, the "new generation" are more attentive to 
customer satisfaction, using innovation at the heart of their logistics services to improve market share. 
This is the era of market strategy driven logistics solutions where conventional efforts are insufficient 
to provide competitiveness, instead it is the flow of products through pharmaceutical wholesalers that 
needs to be managed effectively. The "new generation" wholesaler distributors use ambidextrously 
based supply chain strategy to respond to minute changes in requirements in order to improve their 
performance still further and cement their position in the supply chain. Figure 2 gives a view on some 
of the areas that may provide opportunities for pharmaceutical supply chain improvement in the future. 
 
Figure 2: Opportunities for improving the pharmaceutical supply chain 
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Source: adapted from PricewaterhouseCooper (2011, p. 10) 
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The Boots Alliance Company (UK). 
The Boots Alliance group was created in 2006, by a merger between Alliance UniChem and Boots 
businesses. This new entity is now a leader in the health and luxury value chain in several economic 
territories of the world. Through a variety of buyouts worldwide, the company offers a wide range of 
products and services to its customers. The various acquisitions have enabled the company to engage 
in supply chain explorative and exploitative innovation. 
The leaders of the group seek innovation of supply chain exploitation type because they wish to 
strengthen the company's presence in existing markets. Operating supply chain innovations are the 
most important in its “Pharmaceutical Healthcare Alliance” distribution division. Alliance Healthcare is 
a network of joint ventures and affiliates. For example, Alloga Alphega have the networks, skills and 
business know-how to bring new customized logistics services that the Healthcare Alliance needs to 
consolidate its market position in the physical distribution of medicines. When the company cannot 
provide a number of logistics services on its own account, partnership strategies allow it to provide its 
customers with innovative services. For example, agreements between manufacturers and 
pharmacists play a strategic role in the process of creating new logistics services. Product availability, 
frequency of delivery, accuracy, timeliness and reliability of the treatment of logistics flows are 
guaranteed by the wholesale distributor. Pharmacists are aware that, entrusting the management of 
the logistics of the distribution of these goods to Healthcare, the wholesale distributor allows them to 
increase efficiency and performance. The Healthcare company has also developed new activities for 
the industrial pharmaceutical supply chain businesses that want to outsource their entire logistics 
process flow. These services providers include pre-wholesalers, specialists in the direct delivery to 
pharmacies and drug delivery specialists. 
British wholesalers / distributors also developed supply chain exploration strategy. This strategy can 
be seen in the purchasing policies of Boots pharmacy which has been developing for about 130 years. 
In Britain, Boots has been at the forefront of innovation in customer service. Boots Laboratories 
expertise has been focussed on customer requirements in terms of health and beauty. Further, during 
the whole lifetime of Boots Laboratories, its scientists have been responsible for the development of 
highly innovative products. By merging with the wholesale distributor Alliance UniChem, Boots have 
endeavoured to stabilize its distribution business and take a further step in its process development 
enabling innovative exploration of new areas. Thus, the Alliance Boots business deploys a strategy of 
radical innovation in order to develop logistics services that concentrate on the downstream health 
value chain. Alliance Boots has also signed a partnership agreement with the U.S. company Procter & 
Gamble (P & G). This agreement enables the wholesale distributor to rely on the capabilities of P & G, 
benefiting both from their sales network and the promotion of their pharmacy brands. The wholesaler 
also offers Almus branded generic drugs which are very popular in the UK. These drugs provide 
greater security for patients that use them because their presentation has been designed so that 
pharmacists and customers easily identify generic drugs by simply looking at the carton. The 
packaging gives precise information on the generic drugs contained in the boxes. In addition, Alliance 
Boots has invested in the design and fabrication of quasi-pharmaceutical products for pharmacies. 
Such goods are marketed under the brand Alvita. Finally, the Alliance Boots company has created a 
subsidiary, known as Boots Contract Manufacturing (BCM), which carries out the production of health 
and beauty for itself and for third party companies. Importantly, in order to improve its strategic 
decision making, BCM operates completely independently of the other Alliance Boots subsidiaries 
since 2009. The Alliance Boots company results are positive and their market share continues to 
grow. In 2010, the company achieved a turnover of £ 22.5 billion and a profit of £ 1,360 million. 
AmerisourceBergen Company (US). 
The AmerisourceBergen company was created in 2001 following the merger of Bergen Brunswig Drug 
Co. and AmeriSource Corporation. At the time of their merger, these companies were the second and 
fourth largest wholesale distributors in the United States. To improve its position in the drug supply 
chain, the company has developed new innovations in both supply chain exploitation and exploration. 
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Supply chain exploitation strategy has been developed through the acquisition of companies already 
involved in managing the physical flow of pharmaceutical products. In 2005, AmerisourceBergen 
acquired the wholesale distributor Trent Drugs, and 2006 followed this with Asenda Pharmaceuticals 
and Rep-Pharm. In 2007, they added another wholesale distributor named Bellco Health. Operational 
innovation activities are grouped under the banner of the AmerisourceBergen Drug Corporation 
(ABDC). All activities related to the logistics of branded laboratory drug distribution as well as those 
related to generic drugs are marshalled under that name. Distribution logistics of over-the-counter 
healthcare products, home healthcare supplies and equipment is also placed in this section, which is 
dedicated to the core business of the company. By acquiring other wholesale distributors, the 
company is able to be innovative with the logistics services it offers to its customers. It has succeeded, 
among other things, in surviving in a drug supply chain in which supply chain management practices 
have made significant progress in recent years. This approach gives AmerisourceBergen a sound 
anchorage in the pharmaceutical supply chain. The physical distribution network of the company has 
been greatly improved by exploitative innovation. Currently, it has 26 distribution platforms in the U.S. 
and 8 in Canada. The company has made heavy investments in information systems, which are 
intended to optimize the processing of computer data and to increase the velocity of logistics flows in 
the supply chain. The new technology used by AmerisourceBergen promotes the integrated 
management of flows and the effective treatment of logistics activities, enabling customers’ deliveries 
to be made in very short times without increasing operating costs. Flows that pass through the 
warehouses of wholesale distributors are managed using just in time (JIT) principles. This means that 
the relevant products must spend as little time as possible in platform’s freight company.  
AmerisourceBergen’s supply chain exploration strategy has been allowed to intervene beyond its core 
business, specifically the distribution of pharmaceutical products. Indeed, thanks to several 
acquisitions of companies engaged in activities other than distribution, AmerisourceBergen is now 
able to offer a multitude of services to all stakeholders in the pharmaceutical supply chain as well as 
those of the health value chain. In other words, the pharmaceutical logistics activities have been 
integrated. This means that, in future, the company can control the flow of the value chain of health as 
a whole both upstream and downstream through the supply chain. To do this, two other entities were 
created within the group, the AmerisourceBergen Specialty Group (ABSG) and the 
AmerisourceBergen Packaging Group. The first entity provides solutions to the problems of 
reimbursement and patient compliance for the pharmaceutical companies, medical device 
manufacturers and biotechnology companies. Pharmaceutical companies can rely on the health 
service to monitor steps in the life cycle of a product at both pre-commercialization and 
commercialization. ABSG Pharmaceutical clients are entities looking for services to improve their 
product launches, and at the same time help with their strategies intended to allow them to expand 
into new markets. The company has also developed a number of communication programs in medical 
sciences and is capable of taking over order management. AmerisourceBergen's acquisition of three 
players in the specialists packaging industry (in this case American Health Packaging, Packaging and 
Anderson Brecon Pharmaceuticals Limited) allows them to become involved in the process of drug 
packaging. The entity formed by the merger of the three companies, named AmerisourceBergen 
Packaging Group (ABPG), provides packaging solutions to institutional investors and distributors of 
health and service contracts dedicated to drug manufacturers. It also provides the material necessary 
for the conduct of clinical trials. The innovations that the company has developed within the health 
value chain have had positive effects on performance, which has helped the revenue benefits that are 
central to AmerisourceBergen’s drug distribution business. These have increased steadily between 
2004 and 2009. The company’s annual report shows a turnover of $47.6 billion U.S. in 2004 rising five 
years later to $ 56.1 million U.S. The wholesale distributor AmerisourceBergen is the leading player in 
its market with 42% of the pharmaceutical products distributed. These rewards demonstrate that the 
innovations offered by the company have been extremely successful with consumers. Further 
evidence of success is shown by the ranking in 2010 of the “Good Neighbour Pharmacy” program as 
the provider of the highest quality of service for pharmacies. At the same time, the company received 
an award of excellence for the successful development of very high performance supply chain 
innovations and its ambidextrous strategy. 
Discussion 
Wholesale distributors Alliance Boots and AmerisourceBergen, both demonstrate the use of 
innovation. The extent and value of logistics services or services dedicated to health marketing offered 
by these two companies have different degrees of complexity. The innovation strategies of exploitation 
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and exploration deployed in their supply chain, clearly show that both companies have developed and 
utilized ambidextrous supply chain strategies as defined by Kristal (Kristal et al., 2010). Further, it is 
thanks to these ambidextrous supply chain strategies that both companies were able to combine 
capacity and competitiveness improvements. This, in turn, enabled them to be securely anchored in 
the drug supply chain as well as being more broadly rooted in the health care industry’s value chain. 
By implementing ambidextrous strategies, both companies have significantly expanded their logistics 
services. These now range from simple transport operations to the implementation of complex 
logistics solutions which may include value-added activities such as direct marketing, billing, 
prescription management and advisory activities. Logistics services set up by Boots Alliance and 
AmerisourceBergen can be standardized or feature highly customized bundling. The variety of 
situations observed during the research shows that both wholesale distributors are able to utilize and 
combine innovation in different circumstances. Alliance Boots and AmerisourceBergen can develop 
and design services that meet the needs of their customers, whether those needs have been 
expressed or not. In the first situation, both wholesale distributors are applying demand logic, whereas 
in the second, they are acting in supply mode. The wholesale distributor's ability to adapt to standard 
or complex requests from its clients demonstrates the degree of interaction between them in the 
building-construction or co-modulation and innovative services. The degree of process control shown 
by the two companies highlighted in the research reflects the fact that wholesale distributors are able 
to provide complete in-house services to their customers or subcontract any part of those services if 
necessary. Because of the nature of the contracts between themselves and their customers, Alliance 
Boots and AmerisourceBergen are demonstrated to be logistics operators, integrators or agents of 
logistics services or health services. 
The research showed the extent of the skills of Alliance Boots and AmerisourceBergen within the 
health value chain as well as in the drug supply chain. The economic environment of the healthcare 
industry has changed significantly in recent years and the level of uncertainty has increased 
considerably. Even the highly competitive health value chain, like other value chains, is under 
pressure. Drugs that pass through the pipeline will flow more as easily than in the past, and 
manufacturers make every effort to ensure that the physical flow of drugs is never sluggish. The 
creation of new logistico-differentiated marketing offers have allowed both companies to build 
competitive advantage. The ambidextrous supply chain strategy deployed by Alliance Boots and 
AmerisourceBergen has a positive impact on performance and profit of both companies. Logistics and 
logistico-marketing innovations are seen as quite radical strategies for differentiating the service 
offering. Figure 3 illustrates how pharmaceutical supply chains can be developed with reference to the 
twin axes of innovation and complexity. The implementation of these complex and diverse strategies 
carried out by Alliance Boots and AmerisourceBergen have enabled them to become permanently 
rooted in a sustainable supply drug chain and, more generally, in the health value chain. Thus, 
challenges linked to logistics and logistico-marketing innovation are shown take on great importance 
for the long term success and sustainability of pharmaceutical wholesalers. 
Figure 3: Typology of logistics services offered by pharmaceutical wholesalers 
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Source: adapted from Boissinot and Kacioui-Maurin (2009) 
Conclusion 
This research has highlighted the impact that the deployment of an ambidextrous supply chain 
strategy can have on the capabilities and performance of wholesale distributors in both Britain and the 
United States. We found that applying an ambidextrous supply chain strategy has positive effects on 
strategic capabilities as well as market shares and profits of the companies studied. Further, it has 
demonstrated that an ambidextrous supply chain strategy is a viable approach for wholesale 
distributors to improve their positioning within the pharmaceutical supply chain, or more broadly within 
the health value chain. It is through such policies that the two wholesale distributors studied have been 
able to mobilize external resources and supply chain management as well as building and developing 
their own skills in-house.  
Like all research, this study has a number of limitations. Specifically it only looks at ambidextrous 
supply chain strategy from the perspective of wholesale distributors. Future research could involve the 
study of ambidextrous supply chain strategy and its effects on the entire supply chain as suggested by 
Kauppila (2007) and Kristal, Huang and Roth (2010). Integrated networks foretold the end of 
intermediates and projected the disappearance of pharmaceutical wholesalers, but failed to take 
account of their adaptability. The results of this research show that the wholesalers have survived, 
flourished and indeed influenced the development of pharmaceutical supply chain structure and 
strategy. Despite this, some academic research has remained focused on “dated” wholesaler supply 
chain models, this research has examined some of the new developments and their impact. At a time 
when governments are trying to reduce health care costs in response to straightened financial 
circumstances, better understanding of their role in the pharmaceutical supply chain could be 
invaluable. This paper provides information about the ability of wholesalers to renew their logistics 
services and helps understand their contribution to today’s "new generation" of pharmaceutical supply 
chains as well as to healthcare value chains. Wholesalers’ strategies, whether motivated by their own 
desires for improvement or driven to react to the needs of manufacturers and customers, take time to 
develop and are rarely understood or documented. This research contributes to that understanding 
and may also enable governments to understand the role of “new generation” wholesale distributors 
and thus exert greater control over health expenditures.   
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